• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

AbbVie Touts Subgroup Data in Phase II Atrial Fibrillation Miss

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Nov 08, 2022 at 11:12: AM
via Despite missing its primary endpoint in a Phase II trial, AbbVie is holding out hope that its investigational neurotoxin, AGN-151607, can be effective in preventing postoperative atrial fibrillation in some cardiac surgery patients.

article source
 




Top Bottom
Back
Quote